{"filing":{"accession_number":"0001062993-26-003128","cik":"0002066836","ticker":"CNXU","company_name":"Conexeu Sciences Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2066836/000106299326003128/form8k.htm"},"events":[{"id":5854,"run_id":5134,"accession_number":"0001062993-26-003128","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (1) exercise of 416,667 common stock purchase warrants for $166,667 gross proceeds, with issuance of 416,667 additional incentive warrants; and (2) exercise of 100,000 performance warrants for $100. These transactions are exempt from registration (Regulation S and Rule 506(b)), and the incentive warrants represent dilutive equity issuances. The scale of warrant exercises and the incentive program designed to encourage early exercise of up to 5.7 million outstanding warrants signal material dilution to existing shareholders.","company_name":"Conexeu Sciences Inc.","ticker":"CNXU","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5583,"accession_number":"0001062993-26-003128","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (1) exercise of 416,667 common stock purchase warrants for $166,667 gross proceeds, with issuance of 416,667 additional incentive warrants; and (2) exercise of 100,000 performance warrants for $100. These transactions are exempt from registration (Regulation S and Rule 506(b)), and the incentive warrants represent dilutive equity issuances. The scale of warrant exercises and the incentive program designed to encourage early exercise of up to 5.7 million outstanding warrants signal material dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:33:30.205281+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5583,"accession_number":"0001062993-26-003128","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (1) exercise of 416,667 common stock purchase warrants for $166,667 gross proceeds, with issuance of 416,667 additional incentive warrants; and (2) exercise of 100,000 performance warrants for $100. These transactions are exempt from registration (Regulation S and Rule 506(b)), and the incentive warrants represent dilutive equity issuances. The scale of warrant exercises and the incentive program designed to encourage early exercise of up to 5.7 million outstanding warrants signal material dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:33:30.205281+00:00","company_name":"Conexeu Sciences Inc.","ticker":"CNXU","filing_date":"2026-06-09"}]}